Once-daily Janumet finally gets US FDA OK, boosting Merck's diabetes franchise
This article was originally published in Scrip
Executive Summary
Merck & Co's once-daily combination diabetes treatment Janumet XR has now received US approval a year after the acceptance of the NDA and following a complete response letter last summer.